While human dataparticularly in BD populationsremain limited, evidence points to potential adjunctive benefits, especially in individuals with metabolic or cognitive vulnerabilities
Choose bacteriostatic water for multi-dose vials, as its 0.9% benzyl alcohol helps inhibit microbial growth
Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN3): a 56-week, open-label, randomized clinical trial
The ClinicalTrials.gov registry documents a ConjuChem-sponsored study, NCT00267527 a multicentre, randomised, placebo-controlled, double-blind Phase 2 study of CJC-1295 administered for 12 weeks in HIV-infected patients with HIV-associated visceral obesity, with a registry enrolment estimate of 120 and a start date of December 2005
The FDA's Position on Compounded GLP-1 Agonists The FDA has taken an increasingly firm position on compounded versions of GLP-1 receptor agonists
Pioglitazone should only be initiated by a specialist after careful patient selection and counselling